| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JAAD.2010.06.018 |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:S0190962210006997?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:S0190962210006997?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 20739095 |
| P2093 | author name string | Annegret Kuhn | |
| Gisela Bonsmann | |||
| Vincent Ruland | |||
| P2860 | cites work | Cutaneous lupus erythematosus-treatment with pulsed dye laser | Q30828452 |
| Successful treatment of discoid lupus erythematosus with argon laser | Q30951906 | ||
| Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus | Q33329839 | ||
| Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus | Q33418969 | ||
| The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus | Q33692688 | ||
| Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients | Q33697263 | ||
| Analysis of compact fluorescent lights for use by patients with photosensitive conditions | Q33844384 | ||
| New concepts in antimalarial use and mode of action in dermatology | Q34007922 | ||
| Cutaneous lupus erythematosus | Q34222398 | ||
| Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations | Q34227000 | ||
| Pimecrolimus 1% cream for cutaneous lupus erythematosus | Q34344494 | ||
| The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus | Q34514923 | ||
| The relation between sun protection factor and amount of suncreen applied in vivo | Q34627062 | ||
| Pimecrolimus: a review. | Q35206755 | ||
| UVA-1 cold light treatment of SLE: a double blind, placebo controlled crossover trial | Q35550020 | ||
| Detecting chloroquine retinopathy: electro-oculogram versus colour vision | Q35591207 | ||
| Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients | Q35636940 | ||
| Broad-spectrum photoprotection: the roles of tinted auto windows, sunscreens and browning agents in the diagnosis and treatment of photosensitivity | Q35653285 | ||
| Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature | Q36049718 | ||
| Koebner phenomenon in lupus erythematosus with special consideration of clinical findings | Q36127506 | ||
| Socioeconomic factors in lupus erythematosus | Q36127521 | ||
| Laser treatment of discoid lupus (case report). | Q36493105 | ||
| Cardiomyopathy related to antimalarial therapy with illustrative case report | Q36521126 | ||
| Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies | Q36632600 | ||
| Smoking as a trigger for inflammatory rheumatic diseases | Q36672505 | ||
| Successful treatment of chronic discoid lupus erythematosus with argon laser | Q36846886 | ||
| Phototesting in lupus erythematosus: a 15-year experience | Q74088240 | ||
| Questions answered and a $1 million question raised concerning lupus erythematosus tumidus: is routine laboratory surveillance testing during treatment with hydroxychloroquine for skin disease really necessary | Q74113541 | ||
| Treatment of lupus erythematosus with mepacrine | Q75834093 | ||
| Report of an association between discoid lupus erythematosus and smoking | Q77401511 | ||
| Discoid lupus erythematosus treated with cryotherapy | Q79107055 | ||
| Antimalarial agents: closing the gate on Toll-like receptors? | Q79158393 | ||
| Successful treatment with topical tacrolimus in four cases of discoid lupus erythematosus | Q79433398 | ||
| Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study | Q79473578 | ||
| Desensitization to hydroxychloroquine: alternative interpretations | Q79784916 | ||
| Use of sunscreens to protect against ultraviolet-induced lupus erythematosus | Q80806207 | ||
| Resistance to hydroxychloroquine due to smoking in a patient with lupus erythematosus tumidus | Q81248165 | ||
| The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men; a focus on combined C2/C4 deficiency | Q81433109 | ||
| UV hardening therapy: a novel intervention in patients with photosensitive cutaneous lupus erythematosus | Q82603386 | ||
| The use of topical calcineurin inhibitors in lupus erythematosus: an overview. | Q37001577 | ||
| Tobacco smoking and autoimmune rheumatic diseases | Q37014108 | ||
| Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation | Q37044632 | ||
| Current sunscreen issues: 2007 Food and Drug Administration sunscreen labelling recommendations and combination sunscreen/insect repellent products | Q37165949 | ||
| Topical calcineurin inhibitors in cutaneous lupus erythematosus | Q37271733 | ||
| Implication for photosensitive patients of ultraviolet A exposure in vehicles | Q38575545 | ||
| The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination | Q38637388 | ||
| Antimalarials in the management of discoid and systemic lupus erythematosus | Q39772563 | ||
| Antimalarials for children: indications, toxicities, and guidelines | Q40908987 | ||
| Cigarette smoking and clinically significant drug interactions | Q40952943 | ||
| Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice | Q41564952 | ||
| Dapsone in the treatment of cutaneous lupus erythematosus. | Q41916151 | ||
| Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology | Q41917354 | ||
| The effects of lysosomotropic amines on protein degradation, migration of nonhistone proteins to the nucleus, and cathepsin D in lymphocytes | Q41917407 | ||
| Combination of antimalarial drugs mepacrine and chloroquine in therapy refractory cutaneous lupus erythematosus | Q41921981 | ||
| Antimalarial drug-induced aquagenic-type pruritus in patients with lupus | Q41926769 | ||
| Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine | Q41927634 | ||
| The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus | Q41936373 | ||
| Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking | Q41938899 | ||
| Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine | Q41939243 | ||
| Hydroxychloroquine-associated, photo-induced toxic epidermal necrolysis | Q41940940 | ||
| Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy | Q41946375 | ||
| Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus | Q42667758 | ||
| Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus | Q43273397 | ||
| A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus. | Q43291806 | ||
| Fatal toxic epidermal necrolysis associated with hydroxychloroquine | Q43697994 | ||
| Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus | Q43809460 | ||
| The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus | Q44099092 | ||
| Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod | Q44224055 | ||
| Topical treatment with tacrolimus in lupus erythematosus tumidus | Q44598789 | ||
| Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three cases | Q44681390 | ||
| Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study. | Q45956776 | ||
| The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine | Q46158721 | ||
| Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus | Q46351311 | ||
| Hydroxychloroquine: the cornerstone of lupus therapy | Q46643929 | ||
| Systemic treatment of cutaneous lupus erythematosus | Q46801766 | ||
| The dilemma of hydroxychloroquine screening: new information from the multifocal ERG. | Q46822479 | ||
| Discoid and subacute lupus erythematosus treated with 0.5% R-salbutamol cream | Q46845229 | ||
| Sun-induced life-threatening lupus nephritis | Q46982885 | ||
| Is there a role for quinacrine (Atabrine) in the new millennium? | Q47864582 | ||
| A case of generalized discoid lupus erythematosus: successful treatment with imiquimod cream 5%. | Q50713030 | ||
| Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. | Q53850772 | ||
| Association between Discoid Lupus erythematosus and Cigarette Smoking | Q57274770 | ||
| An exacerbation of SLE after visiting a tanning salon | Q69495509 | ||
| Cutaneous lupus treated with topical tretinoin: a case report | Q70229685 | ||
| Pulse methylprednisolone therapy for persistent subacute cutaneous lupus | Q71419779 | ||
| Ultraviolet-A1 (340-400 nm) irradiation therapy in systemic lupus erythematosus | Q71683321 | ||
| Photoexacerbation of cutaneous lupus erythematosus due to ultraviolet a emissions from a photocopier | Q71970907 | ||
| Ultraviolet-A1 irradiation decreases clinical disease activity and autoantibodies in patients with systemic lupus erythematosus | Q72079206 | ||
| Carbon dioxide laser resurfacing of facial scarring secondary to chronic discoid lupus erythematosus | Q73167390 | ||
| Treatment of localized discoid lupus erythematosus with tazarotene | Q73202265 | ||
| Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test | Q73332138 | ||
| Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment | Q73826137 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cutaneous lupus erythematosus | Q18553226 |
| P304 | page(s) | e179-93 | |
| P577 | publication date | 2010-08-23 | |
| P1433 | published in | Journal of the American Academy of Dermatology | Q15757046 |
| P1476 | title | Cutaneous lupus erythematosus: Update of therapeutic options | |
| P478 | volume | 65 |
| Q38851093 | Advances in the treatment of cutaneous lupus erythematosus |
| Q41911782 | Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study |
| Q50229972 | Beneficial effect of hydroxychloroquine on cutaneous vasculitis in a Japanese patient with systemic lupus erythematosus |
| Q38731631 | Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment |
| Q44746734 | Cutaneous lupus erythematosus and skin manifestations in systemic lupus erythematosus |
| Q37590352 | Cutaneous lupus erythematosus: diagnosis and treatment |
| Q38857518 | Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus |
| Q34194291 | Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria |
| Q27015934 | Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature |
| Q36257051 | Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis |
| Q36907616 | Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus |
| Q35289684 | Efficacy of Intravenous Immunoglobulin Monotherapy in Patients with Cutaneous Lupus Erythematosus: Results of Proof-of-Concept Study |
| Q41927491 | Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus |
| Q57146778 | Fatigue in systemic lupus erythematosus and other autoimmune skin diseases |
| Q90157934 | Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy |
| Q36240425 | Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence |
| Q36421686 | Hydroxychloroquine-induced reversible hypomnesis in a patient with reticular erythematous mucinosis |
| Q38883883 | Immunomodulators in SLE: Clinical evidence and immunologic actions |
| Q51150943 | Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. |
| Q39005980 | Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus |
| Q38731966 | Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience |
| Q37609869 | Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects |
| Q92625510 | Management strategies and future directions for systemic lupus erythematosus in adults |
| Q53343146 | Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lup |
| Q34937950 | Mucocutaneous manifestations in juvenile-onset systemic lupus erythematosus: a review of literature |
| Q38178160 | Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review. |
| Q33913777 | Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea |
| Q35764302 | Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis |
| Q52836583 | S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). |
| Q93193261 | Systemic lupus erythematosus: Diagnosis and clinical management |
| Q44443369 | Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus? |
| Q48332079 | The Cutaneous Spectrum of Lupus Erythematosus. |
| Q35692998 | The Diagnosis and Treatment of Systemic Lupus Erythematosus |
| Q41915761 | The effect of hydroxychloroquine on lupus erythematosus-like skin lesions in MRL/lpr mice |
| Q38850089 | Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects |
| Q34548422 | Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria. |
| Q35633324 | Treatment of cutaneous lupus |
| Q30249011 | Treatment of primary Sjögren syndrome |
| Q27005906 | Unmet medical needs in systemic lupus erythematosus |
| Q38708002 | Upcoming Therapeutic Targets in Cutaneous Lupus Erythematous |
| Q58080516 | [37-year-old male with confluent papules and arcuate erythematosquamous plaques on the upper trunk and arms : Preparation for the specialist examination: part 22] |
| Q83869346 | [Skin manifestations in lupus erythematosus: clinical aspects and therapy] |
Search more.